- Open
- 1843.00
- High
- 1870.00
- Low
- 1842.50
- Close
- 1856.50
- Change
- -12.50 (-0.67%)
- Volume
- 3,127,039
| 15 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 14 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 13 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 12 Oct 2026 | 15:30:01 | Director/PDMR Shareholding |
| 5 Mar 2026 | 2025 Annual Financial Report | |
| 27 Feb 2025 | 2024 Annual Financial Report | |
| 1 Mar 2024 | 2023 Annual Financial Report |
GSK plc is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines. It focuses on four core therapeutic areas: respiratory, immunology and inflammation, oncology, and infectious diseases. GSK operates globally and aims to impact the health of a significant number of people through its specialty medicines and vaccines.
| 15 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 14 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 13 Oct 2026 | 15:30:00 | Director/PDMR Shareholding |
| 12 Oct 2026 | 15:30:01 | Director/PDMR Shareholding |
| 5 Mar 2026 | 2025 Annual Financial Report | |
| 27 Feb 2025 | 2024 Annual Financial Report | |
| 1 Mar 2024 | 2023 Annual Financial Report |
GSK plc is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines. It focuses on four core therapeutic areas: respiratory, immunology and inflammation, oncology, and infectious diseases. GSK operates globally and aims to impact the health of a significant number of people through its specialty medicines and vaccines.
| 8 Oct 2026 |
| 15:00:01 |
| Wendy Becker CBE - New Directorship |
| 13 Oct 2026 |
| RBC holds on GSK ahead of third-quarter results as HIV cliff looms |
| 12 Oct 2026 | 10 hottest ISA shares, funds and trusts: week ended 9 October 2026 |
| 30 Sept 2026 | Can GSK shares outperform FTSE 100 index over the long run? |
| 30 Sept 2026 | M&G and Aviva among dozen FTSE 100 dividend payers in October |
| 29 Sept 2026 | FTSE 100: oil shares fall as pharma provides support |
| 29 Sept 2026 | GSK's cancer pipeline undervalued, says Jefferies after science chief chat |
Lord Hayward and Lord Balfe have interests in this issuer
| 8 Oct 2026 |
| 15:00:01 |
| Wendy Becker CBE - New Directorship |
| 13 Oct 2026 |
| RBC holds on GSK ahead of third-quarter results as HIV cliff looms |
| 12 Oct 2026 | 10 hottest ISA shares, funds and trusts: week ended 9 October 2026 |
| 30 Sept 2026 | Can GSK shares outperform FTSE 100 index over the long run? |
| 30 Sept 2026 | M&G and Aviva among dozen FTSE 100 dividend payers in October |
| 29 Sept 2026 | FTSE 100: oil shares fall as pharma provides support |
| 29 Sept 2026 | GSK's cancer pipeline undervalued, says Jefferies after science chief chat |
Lord Hayward and Lord Balfe have interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £192.80bn | +0.0% | |
GSKGSK plc | £75.10bn | +0.1% |
| £1.94bn | +0.5% | |
| £1.85bn | -0.1% | |
| £44m | -0.4% | |
| £2m | +0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £192.80bn | +0.0% | |
GSKGSK plc | £75.10bn | +0.1% |
| £1.94bn | +0.5% | |
| £1.85bn | -0.1% | |
| £44m | -0.4% | |
| £2m | +0.1% |
